https://peptide.exchange/move/semaglutide-employment-study-wegovy-work-hoursPeptide Exchangeen2026-11-03T05:02:00.000ZSemaglutide employment study ties Wegovy to longer work hours in Denmark https://peptide.exchange/move/malaysia-seizes-unapproved-retatrutidePeptide Exchangeen2026-11-03T04:40:00.000ZMalaysia seizes 697 units of unapproved retatrutide as Lilly readies its FDA filing https://peptide.exchange/move/bivamelagon-license-deal-setmelanotide-royaltyPeptide Exchangeen2026-11-03T03:51:00.000ZBivamelagon license deal cuts setmelanotide royalty to 1 percent https://peptide.exchange/move/efpeglenatide-launch-korea-undercuts-mounjaroPeptide Exchangeen2026-11-02T05:03:00.000ZEfpeglenatide launch in Korea undercuts Mounjaro and Wegovy on price https://peptide.exchange/move/retatrutide-weight-loss-plateau-evidencePeptide Exchangeen2026-11-02T04:14:00.000ZRetatrutide weight loss plateau hopes outpace the Phase 3 evidence https://peptide.exchange/move/wegovy-pill-prescriptions-weekly-highPeptide Exchangeen2026-11-02T03:55:00.000ZWegovy pill prescriptions set a US weekly high as Lilly keeps its lead